Tertiary lymphoid structures signature predicts prognosis and clinical benefits from neoadjuvant chemotherapy and PD-1 blockade in colorectal adenocarcinoma

The CRC-specific TLS signature identifies patients with favorable prognosis and enhanced responses to chemotherapy and PD-1 blockade, including MSS CRC resistant to immune checkpoint blockade. TLS abundance reflects an immunogenic TME, offering a biomarker for personalized treatment strategies.